Related Experiment Videos

Curcumin sensitizes non-small cell lung cancer cell anoikis through reactive oxygen species-mediated Bcl-2

Varisa Pongrakhananon1, Ubonthip Nimmannit, Sudjit Luanpitpong

  • 1Chulalongkorn University, Bangkok, 10330, Thailand.

Apoptosis : an International Journal on Programmed Cell Death
|February 4, 2010
PubMed

Insights

Curcumin enhances anoikis, a cell death process crucial for preventing tumor metastasis, by downregulating Bcl-2. This mechanism, involving superoxide anion and proteasomal degradation, offers a new strategy for metastatic cancer treatment.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Pharmacology

Background:

  • Anoikis, or apoptosis due to cell detachment, inhibits tumor metastasis.
  • Anti-apoptotic proteins Bcl-2 and Cav-1 are linked to metastasis and apoptosis resistance.
  • Curcumin, from turmeric, shows anti-tumorigenic properties, but its mechanisms are unclear.

Purpose of the Study:

  • Investigate curcumin's effect on anoikis as an anti-tumorigenic mechanism.
  • Evaluate the roles of Bcl-2 and Cav-1 in curcumin-induced anoikis.
  • Elucidate the signaling pathways involved in curcumin's action.

Main Methods:

  • Ectopic expression of Bcl-2 and Cav-1 in lung carcinoma H460 cells.
  • Treatment with curcumin and various reactive oxygen species (ROS) scavengers.
  • Analysis of protein expression, cell apoptosis, and degradation pathways (ubiquitin-proteasomal).

Main Results:

  • Bcl-2 and Cav-1 overexpression conferred anoikis resistance.
  • Curcumin downregulated Bcl-2, enhancing anoikis, but did not affect Cav-1.
  • Superoxide anion, not other ROS, mediated curcumin's Bcl-2 downregulation via ubiquitin-proteasomal degradation.

Conclusions:

  • Curcumin promotes anoikis by targeting Bcl-2 for proteasomal degradation.
  • Superoxide anion is a key mediator in curcumin's effect on Bcl-2.
  • This pathway represents a novel therapeutic strategy against metastatic cancers.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...